메뉴 건너뛰기




Volumn 72, Issue 12, 2012, Pages 1273-1285

"Combi-targeting" mitozolomide: Conferring novel signaling inhibitory properties to an abandoned DNA alkylating agent in the treatment of advanced prostate cancer

Author keywords

DNA damage; epidermal growth factor receptor (EGFR); mitozolomide; prostate; temozolomide

Indexed keywords

ALKYLATING AGENT; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GEFITINIB; JDF 04R; JDF 12; LIPOCORTIN 5; MITOZOLOMIDE; SULFORHODAMINE B; UNCLASSIFIED DRUG;

EID: 84864285448     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22475     Document Type: Article
Times cited : (8)

References (28)
  • 2
    • 0036835534 scopus 로고    scopus 로고
    • Sequencing hormonal ablation and radiotherapy in prostate cancer: A molecular and therapeutic prespective (Review)
    • Hill B, Kyprianou N,. Sequencing hormonal ablation and radiotherapy in prostate cancer: A molecular and therapeutic prespective (Review). Oncol Rep 2002; 9: 1151-1156.
    • (2002) Oncol Rep , vol.9 , pp. 1151-1156
    • Hill, B.1    Kyprianou, N.2
  • 3
    • 22144475857 scopus 로고    scopus 로고
    • Recent progress in management of advanced prostate cancer
    • Kantoff P,. Recent progress in management of advanced prostate cancer. Oncology (Williston Park) 2005; 19: 631-636. (Pubitemid 350042593)
    • (2005) Oncology , vol.19 , Issue.5 , pp. 631-636
    • Kantoff, P.1
  • 4
    • 36248968106 scopus 로고    scopus 로고
    • Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in chinese patients: Experience of a single center
    • DOI 10.1159/000109714
    • Zhang HL, Ye DW, Yao XD, Dai B, Zhang SL, Shen YJ, Zhu Y, Zhang W,. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: Experience of a single center. Urol Int 2007; 79: 307-311. (Pubitemid 350136515)
    • (2007) Urologia Internationalis , vol.79 , Issue.4 , pp. 307-311
    • Zhang, H.L.1    Ye, D.W.2    Yao, X.D.3    Dai, B.4    Zhang, S.L.5    Shen, Y.J.6    Zhu, Y.7    Zhang, W.8
  • 5
    • 4444242518 scopus 로고    scopus 로고
    • Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells
    • DOI 10.1002/jcp.20045
    • Sgambato A, Camerini A, Faraglia B, Ardito R, Bianchino G, Spada D, Boninsegna A, Valentini V, Cittadini A,. Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells. J Cell Physiol 2004; 201: 97-105. (Pubitemid 39187048)
    • (2004) Journal of Cellular Physiology , vol.201 , Issue.1 , pp. 97-105
    • Sgambato, A.1    Camerini, A.2    Faraglia, B.3    Ardito, R.4    Bianchino, G.5    Spada, D.6    Boninsegna, A.7    Valentini, V.8    Cittadini, A.9
  • 6
    • 0020933452 scopus 로고
    • Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors
    • Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH,. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1983; 1: 511-529.
    • (1983) Mol Biol Med , vol.1 , pp. 511-529
    • Sato, J.D.1    Kawamoto, T.2    Le, A.D.3    Mendelsohn, J.4    Polikoff, J.5    Sato, G.H.6
  • 9
    • 0242692686 scopus 로고    scopus 로고
    • Growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer therapy
    • DOI 10.1097/01.ju.0000095022.80033.d3
    • Blackledge G,. Growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer therapy. J Urol 2003; 170: S77-S83 discussion S83. (Pubitemid 37413947)
    • (2003) Journal of Urology , vol.170 , Issue.6
    • Blackledge, G.1    Sellers, W.R.2    Smith, M.R.3
  • 10
    • 0030993717 scopus 로고    scopus 로고
    • Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials
    • DOI 10.1016/S0305-7372(97)90019-0
    • Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C,. Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997; 23: 35-61. (Pubitemid 27273454)
    • (1997) Cancer Treatment Reviews , vol.23 , Issue.1 , pp. 35-61
    • Newlands, E.S.1    Stevens, M.F.G.2    Wedge, S.R.3    Wheelhouse, R.T.4    Brock, C.5
  • 11
    • 0028858706 scopus 로고
    • Increased killing of prostate, breast, colon, and lung tumor cells by the combination of inactivators of O6-alkylguanine-DNA alkyltransferase and N,N'-bis(2-chloroethyl)-N-nitrosourea
    • Pegg AE, Swenn K, Chae MY, Dolan ME, Moschel RC,. Increased killing of prostate, breast, colon, and lung tumor cells by the combination of inactivators of O6-alkylguanine-DNA alkyltransferase and N,N'-bis(2-chloroethyl)-N- nitrosourea. Biochem Pharmacol 1995; 50: 1141-1148.
    • (1995) Biochem Pharmacol , vol.50 , pp. 1141-1148
    • Pegg, A.E.1    Swenn, K.2    Chae, M.Y.3    Dolan, M.E.4    Moschel, R.C.5
  • 12
    • 33745123646 scopus 로고    scopus 로고
    • The combi-targeting concept: Synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR)
    • DOI 10.1021/jm0600390
    • Domarkas J, Dudouit F, Williams C, Qiyu Q, Banerjee R, Brahimi F, Jean-Claude BJ,. The combi-targeting concept: Synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR). J Med Chem 2006; 49: 3544-3552. (Pubitemid 43902460)
    • (2006) Journal of Medicinal Chemistry , vol.49 , Issue.12 , pp. 3544-3552
    • Domarkas, J.1    Dudouit, F.2    Williams, C.3    Qiyu, Q.4    Banerjee, R.5    Brahimi, F.6    Jean-Claude, B.J.7
  • 13
    • 0027501429 scopus 로고
    • Schedule-dependent synergism of edatrexate and cisplatin in combination in the A549 lung-cancer cell line as assessed by median-effect analysis
    • DOI 10.1007/BF00686223
    • Perez EA, Hack FM, Webber LM, Chou TC,. Schedule-dependent synergism of edatrexate and cisplatin in combination in the A549 lung-cancer cell line as assessed by median-effect analysis. Cancer Chemother Pharmacol 1993; 33: 245-250. (Pubitemid 23361074)
    • (1993) Cancer Chemotherapy and Pharmacology , vol.33 , Issue.3 , pp. 245-250
    • Perez, E.A.1    Hack, F.M.2    Webber, L.M.3    Chou, T.-C.4
  • 14
    • 0030514288 scopus 로고    scopus 로고
    • Comparison of two colorimetric assays as cytotoxicity endpoints for an in vitro screen for antitumour agents
    • Fricker SP, Buckley RG,. Comparison of two colorimetric assays as cytotoxicity endpoints for an in vitro screen for antitumor agents. Anticancer Res 1996; 16: 3755-3760. (Pubitemid 27085044)
    • (1996) Anticancer Research , vol.16 , Issue.6 , pp. 3755-3760
    • Fricker, S.P.1    Buckley, R.G.2
  • 15
    • 0035119740 scopus 로고    scopus 로고
    • Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: A novel tumor targeting strategy
    • Matheson SL, McNamee J, Jean-Claude BJ,. Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: A novel tumor targeting strategy. J Pharmacol Exp Ther 2001; 296: 832-840. (Pubitemid 32187355)
    • (2001) Journal of Pharmacology and Experimental Therapeutics , vol.296 , Issue.3 , pp. 832-840
    • Matheson, S.L.1    McNamee, J.2    Jean-Claude, B.J.3
  • 16
    • 0036899978 scopus 로고    scopus 로고
    • Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer
    • Sirotnak FM, She Y, Lee F, Chen J, Scher HI,. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Clin Cancer Res 2002; 8: 3870-3876. (Pubitemid 35424782)
    • (2002) Clinical Cancer Research , vol.8 , Issue.12 , pp. 3870-3876
    • Sirotnak, F.M.1    She, Y.2    Lee, F.3    Chen, J.4    Scher, H.I.5
  • 17
    • 0000360901 scopus 로고
    • Synthesis of potential anticancer agents. XXIX. 5-Diazoimidazole-4- carboxamide and 5-diazo-v-triazole-4-carboxamide
    • Shealy YF, Struck RF, Holum LB, Montgomery JA,. Synthesis of potential anticancer agents. XXIX. 5-Diazoimidazole-4-carboxamide and 5-diazo-v-triazole- 4-carboxamide. J Org Chem 1961; 26: 2396-2401.
    • (1961) J Org Chem , vol.26 , pp. 2396-2401
    • Shealy, Y.F.1    Struck, R.F.2    Holum, L.B.3    Montgomery, J.A.4
  • 19
    • 0023123974 scopus 로고
    • Antitumor imidazotetrazines. 14. Synthesis and antitumor activity of 6- and 8-substituted imidazo[5,1-d]-1,2,3,5-tetrazinones and 8-substituted pyrazolo[5,1-d]-1,2,3,5-tetrazinones
    • DOI 10.1021/jm00385a018
    • Lunt E, Newton CG, Smith C, Stevens GP, Stevens MFG, Straw CG, Walsh RJA, Warren PJ, Fizames C, et al. Antitumor imidazotetrazines. 14. Synthesis and antitumor activity of 6- and 8-substituted imidazo[5,1-d]-1,2,3,5-tetrazinones and 8-substituted pyrazolo[5,1-d]-1,2,3,5-tetrazinones. J Med Chem 1987; 30: 357-366. (Pubitemid 17003808)
    • (1987) Journal of Medicinal Chemistry , vol.30 , Issue.2 , pp. 357-366
    • Lunt, E.1    Newton, C.G.2    Smith, C.3
  • 20
    • 37049075486 scopus 로고
    • Antitumor imidazotetrazines. Part 31. the synthesis of isotopically labeled temozolomide and a multinuclear (1H, 13C, 15N) magnetic resonance investigation of temozolomide and mitozolomide. J Chem Soc
    • Wheelhouse RT, Wilman DEV, Thomson W, Stevens MFG,. Antitumor imidazotetrazines. Part 31. The synthesis of isotopically labeled temozolomide and a multinuclear (1H, 13C, 15N) magnetic resonance investigation of temozolomide and mitozolomide. J Chem Soc. Perkin Trans 1: 1995; 249-252.
    • (1995) Perkin Trans , vol.1 , pp. 249-252
    • Wheelhouse, R.T.1    Wilman, D.E.V.2    Thomson, W.3    Stevens, M.F.G.4
  • 21
    • 33845688396 scopus 로고    scopus 로고
    • Type II combi-molecules: Design and binary targeting properties of the novel triazolinium-containing molecules JDD36 and JDE05
    • DOI 10.1097/CAD.0b013e3280115fe8, PII 0000181320070200000008
    • Qiu Q, Domarkas J, Banerjee R, Katsoulas A, McNamee JP, Jean-Claude BJ,. Type II combi-molecules: Design and binary targeting properties of the novel triazolinium-containing molecules JDD36 and JDE05. Anti Cancer Drugs 2007; 18: 171-177. (Pubitemid 44967427)
    • (2007) Anti-Cancer Drugs , vol.18 , Issue.2 , pp. 171-177
    • Qiu, Q.1    Domarkas, J.2    Banerjee, R.3    Katsoulas, A.4    McNamee, J.P.5    Jean-Claude, B.J.6
  • 22
    • 0035893560 scopus 로고    scopus 로고
    • Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo
    • Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL,. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001; 61: 8887-8895. (Pubitemid 34013905)
    • (2001) Cancer Research , vol.61 , Issue.24 , pp. 8887-8895
    • Moulder, S.L.1    Yakes, F.M.2    Muthuswamy, S.K.3    Bianco, R.4    Simpson, J.F.5    Arteaga, C.L.6
  • 23
    • 0141792695 scopus 로고    scopus 로고
    • The combi-targeting concept: Chemical dissection of the dual targeting properties of a series of "combi-triazenes"
    • DOI 10.1021/jm030142e
    • Rachid Z, Brahimi F, Katsoulas A, Teoh N, Jean-Claude BJ,. The combi-targeting concept: Chemical dissection of the dual targeting properties of a series of "Combi-Triazenes ". J Med Chem 2003; 46: 4313-4321. (Pubitemid 37153012)
    • (2003) Journal of Medicinal Chemistry , vol.46 , Issue.20 , pp. 4313-4321
    • Rachid, Z.1    Brahimi, F.2    Katsoulas, A.3    Teoh, N.4    Jean-Claude, B.J.5
  • 24
    • 0021795414 scopus 로고
    • Experimental antitumor activity against murine tumor model systems of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin- 4(3H)-one (mitozolomide), a novel broad-spectrum agent
    • Hickman JA, Stevens MF, Gibson NW, Langdon SP, Fizames C, Lavelle F, Atassi G, Lunt E, Tilson RM,. Experimental antitumor activity against murine tumor model systems of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5- tetrazin-4(3 H)-one (mitozolomide), a novel broad-spectrum agent. Cancer Res 1985; 45: 3008-3013. (Pubitemid 15007165)
    • (1985) Cancer Research , vol.45 , Issue.7 , pp. 3008-3013
    • Hickman, J.A.1    Stevens, M.F.G.2    Gibson, N.W.3
  • 25
    • 32144441841 scopus 로고    scopus 로고
    • Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells
    • DOI 10.1016/j.bcp.2005.12.009, PII S0006295205008348
    • Pu Y-S, Hsieh M-W, Wang C-W, Liu G-Y, Huang C-Y, Lin C-C, Guan J-Y, Lin S-R, Hour T-C,. Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells. Biochem Pharmacol 2006; 71: 751-760. (Pubitemid 43208831)
    • (2006) Biochemical Pharmacology , vol.71 , Issue.6 , pp. 751-760
    • Pu, Y.-S.1    Hsieh, M.-W.2    Wang, C.-W.3    Liu, G.-Y.4    Huang, C.-Y.5    Lin, C.-C.6    Guan, J.-Y.7    Lin, S.-R.8    Hour, T.-C.9
  • 26
    • 5044220098 scopus 로고    scopus 로고
    • Sustained antiproliferative mechanisms by RB24, a targeted precursor of multiple inhibitors of epidermal growth factor receptor and a DNA alkylating agent in the A431 epidermal carcinoma of the vulva cell line
    • DOI 10.1038/sj.bjc.6602098
    • Banerjee R, Rachid Z, Qiu Q, McNamee JP, Tari AM, Jean-Claude BJ,. Sustained antiproliferative mechanisms by RB24, a targeted precursor of multiple inhibitors of epidermal growth factor receptor and a DNA alkylating agent in the A431 epidermal carcinoma of the vulva cell line. Br J Cancer 2004; 91: 1066-1073. (Pubitemid 39336244)
    • (2004) British Journal of Cancer , vol.91 , Issue.6 , pp. 1066-1073
    • Banerjee, R.1    Rachid, Z.2    Qiu, Q.3    McNamee, J.P.4    Tari, A.M.5    Jean-Claude, B.J.6
  • 27
    • 77953759248 scopus 로고    scopus 로고
    • The combi-targeting concept: Selective targeting of the epidermal growth factor receptor (EGFR)- and Her2-expressing cancer cells by the complex combi-molecule RB24 (NSC 741279)
    • Banerjee R, Huang Y, McNamee JP, Todorova MI, Jean-Claude BJ,. The combi-targeting concept: Selective targeting of the epidermal growth factor receptor (EGFR)- and Her2-expressing cancer cells by the complex combi-molecule RB24 (NSC 741279). J Pharmacol Exp Ther 2010; 334: 9-20.
    • (2010) J Pharmacol Exp Ther , vol.334 , pp. 9-20
    • Banerjee, R.1    Huang, Y.2    McNamee, J.P.3    Todorova, M.I.4    Jean-Claude, B.J.5
  • 28
    • 77950831852 scopus 로고    scopus 로고
    • Subcellular distribution of a fluorescence-labeled combi-molecule designed to block epidermal growth factor receptor tyrosine kinase and damage DNA with a green fluorescent species
    • Todorova M, Larroque A-L, Dauphin-Pierre S, Fang YQ, Jean-Claude BJ,. Subcellular distribution of a fluorescence-labeled combi-molecule designed to block epidermal growth factor receptor tyrosine kinase and damage DNA with a green fluorescent species. Mol Cancer Ther 2010; 9: 869-882.
    • (2010) Mol Cancer Ther , vol.9 , pp. 869-882
    • Todorova, M.1    Larroque, A.-L.2    Dauphin-Pierre, S.3    Fang, Y.Q.4    Jean-Claude, B.J.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.